The company's platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases. Its core technologies include the SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.
Cyborg Score Rationale
The FDA granted RMAT designation to SENTI-202, a potential first-in-class logic gated off-the-shelf CAR-NK investigational therapy for relapsed/refractory hematologic malignancies including AML, supporting clinical progress. However, the stock has a market cap of $24.84 million and a price-to-earnings ratio of -0.28, reflecting early-stage financial challenges.
Top Insights
Senti Bio completed enrollment in Phase 1 trial of SENTI-202 in February 2026
Data from 20 patients (18 with evaluable responses) in the ongoing multinational SENTI-202 trial showed high efficacy with 50% ORR and 42% CR/CRh
SENTI-202 holds RMAT designation; the company plans FDA discussions in H1 2026 and is designing a potential pivotal registration program and exploring expansion to newly diagnosed and pediatric AML
The stock has been given an average rating of "Moderate Buy" by brokerages with an average 1-year price objective of $9.00